Friedreich Ataxia
72
14
21
43
Key Insights
Highlights
Success Rate
98% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
1.4%
1 terminated out of 72 trials
97.7%
+11.2% vs benchmark
6%
4 trials in Phase 3/4
23%
10 of 43 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 43 completed trials
Clinical Trials (72)
Longitudinal Analysis of Oral Communication in Friedreich's Ataxia
Digital Outcome Assessment Using AI Active Gaming and Motion Capture in Friedreich Ataxia
Study of LX2006 Gene Therapy in Friedreich Ataxia Cardiomyopathy
Characterisation of the Cognitive Profile of Patients Suffering From Friedreich's Ataxia
A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their Babies
A Study to Assess Nomlabofusp in Adolescents and Children With Friedreich's Ataxia
A Study to Learn More About the Effects and Long-Term Safety of Omaveloxolone (BIIB141) in Children and Teens With Friedreich's Ataxia
Clinical Course Of Disease In Participants With FA-CM
Characterization of the Interruptions of the GAA Expansion and Study of Their Influence on the Severity of Friedreich's Ataxia
Evaluation of the Effect of Artesunate in Friedreich Ataxia (FA)
An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia
A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old
Efficacy of Omaveloxolone Treatment for Dysphagia in French Patients With Friedreich's Ataxia
A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors
A Study to Assess the Efficacy and Safety of Vatiquinone for the Treatment of Participants With Friedreich Ataxia
Friedreich Ataxia Nerve Ultrasund
Patient-reported, Health Economic and Psychosocial Outcomes in Friedreich Ataxia
Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia
A Study to Learn About the Effects and Safety of RTA 408 (Omaveloxolone) in People Aged 16 to 40 With Friedreich's Ataxia
Measurement of Frataxin mRNA in Biofluids